Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dr Reddys Laboratories (RDY) EBIT (2016 - 2025)

Historic EBIT for Dr Reddys Laboratories (RDY) over the last 17 years, with Q4 2025 value amounting to $159.9 million.

  • Dr Reddys Laboratories' EBIT fell 2788.94% to $159.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $794.9 million, marking a year-over-year decrease of 291.13%. This contributed to the annual value of $842.0 million for FY2025, which is 356.7% up from last year.
  • According to the latest figures from Q4 2025, Dr Reddys Laboratories' EBIT is $159.9 million, which was down 2788.94% from $203.8 million recorded in Q1 2025.
  • Over the past 5 years, Dr Reddys Laboratories' EBIT peaked at $221.7 million during Q4 2024, and registered a low of $19.0 million during Q4 2021.
  • For the 5-year period, Dr Reddys Laboratories' EBIT averaged around $169.6 million, with its median value being $180.1 million (2024).
  • Per our database at Business Quant, Dr Reddys Laboratories' EBIT plummeted by 8173.08% in 2021 and then skyrocketed by 69361.84% in 2022.
  • Dr Reddys Laboratories' EBIT (Quarter) stood at $19.0 million in 2021, then surged by 693.62% to $150.8 million in 2022, then surged by 37.53% to $207.4 million in 2023, then rose by 6.91% to $221.7 million in 2024, then dropped by 27.89% to $159.9 million in 2025.
  • Its EBIT was $159.9 million in Q4 2025, compared to $203.8 million in Q1 2025 and $221.7 million in Q4 2024.